“‘Someday’ is Now!”: Anpac Bio & medische partners vieren ‘National Cancer Prevention Month’ met mijlpaal van meer dan 60.000 liquide biopsietests

Anpac Bio-Medical Science Company CEO Dr. Chris Yu inspects one of the company's proprietary "Cancer Differentiation Analysis" (CDA) liquid biopsy technology devices before screening simple, standard blood tests signals of early disease. Anpac Bio's CDA technology consistently detects 26+ cancers, with a 75%-90% sensitivity/specificity rates, usually identifying the disease at its earliest stages. And it does so without any harmful side effects in patients; generating far fewer "false positives"; at a cost substantially lower than traditional testing; and generating results within minutes of sample submission. Fully-commercialized with 200 patents filed worldwide, Anpac Bio and its respected medical research partners are celebrating #NationalCancerPreventionMonth by surpassing a new global milestone: processing 60,000+ independently-corroborated CDA tests for early cancer screening and detection; as well as monitoring cancer treatment, effectiveness, and recurrence. (Photo: Business Wire)

SACRAMENTO, Calif.--()--Anpac Bio-Medical Science Company (Anpac Bio) en zijn internationaal vermaarde partners in medisch onderzoek en ziekenhuizen vieren “Wereldkankerdag” (#WorldCanderDay) en “National Cancer Prevention Month” (#NationalCancerPreventionMonth) met een nieuwe, mondiale mijlpaal: wereldwijd zijn meer dan 60.000, onafhankelijk bekrachtigde liquide biopsietests met “Cancer Differentiation Analysis” (CDA) van Anpac Bio toegepast.

De wereldwijd vermaarde Tweede Militaire Medische Universiteit en het daaraan gelieerde ziekenhuis Changhai in Shanghai, China, hebben sinds 2014 meer dan 4000 CDA-tests uitgevoerd.

Deze bekendmaking is officieel geldend in de originele brontaal. Vertalingen zijn slechts als leeshulp bedoeld en moeten worden vergeleken met de tekst in de brontaal, die als enige rechtsgeldig is.

Contacts

Anpac Bio-Medical Science Company
Drisha Leggitt, 916-206-2553
Drisha_Leggitt@AnpacBio.com

Contacts

Anpac Bio-Medical Science Company
Drisha Leggitt, 916-206-2553
Drisha_Leggitt@AnpacBio.com